Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386645 · ClinicalTrials.gov registry record · NA
Effect of Dietary Glycemic Index on Beta-cell Function
A NA study of PreDiabetes and Oxidative Stress, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT01386645 is a NA study of PreDiabetes and Oxidative Stress that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 56 participants, below the 690-participant average among 89 other PreDiabetes trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01386645, a NA study of PreDiabetes and Oxidative Stress, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will determine if increasing the highs and lows of blood glucose levels (glycemic variability) impairs insulin secretion in people with impaired glucose tolerance and/or impaired fasting glucose who are at risk for developing type 2 diabetes. Furthermore, the study will determine whether changes in beta-cell function are associated with glycemic variability and whether they are mediated by oxidative stress. To decrease or increase glycemic variability the study will provide subjects with special diets containing either low or high glycemic index foods respectively for 4 weeks. To determine if oxidative stress is a mediator, subjects on the high glycemic index diet will take either placebo or the anti-oxidant N-acetylcysteine. The study will address the hypothesis that increased glycemic variability results in increased oxidative stress and thereby exacerbates beta-cell dysfunction in individuals with impaired glucose tolerance and/or impaired fasting glucose. The findings may have important implications for the development of effective strategies aimed at the prevention and treatment of type 2 diabetes. In addition, understanding the contribution of dietary glycemic index to beta-cell dysfunction in subjects with pre-diabetes may have a significant public health impact, including changes to dietary counseling and promotion of healthier eating patterns.
Conditions Studied
Interventions
- OTHER low glycemic index (LGI) diet
- OTHER high glycemic index (HGI) diet plus placebo (PLAC)
- DRUG high glycemic index diet plus N-acetylcysteine
Study Locations (1)
Washington
- VA Puget Sound Health Care System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2011-07 |
| Est. Completion | 2019-08-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01386645
The ClinicalTrials.gov registry entry for NCT01386645 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 690-participant average among 89 other PreDiabetes trials with a reported enrollment target (92% lower). The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with PreDiabetes appearing as the primary indexed condition, and to 3 interventions - of which low glycemic index (LGI) diet is the first listed.
NCT01386645 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01386645 about?
NCT01386645 is a clinical study titled "Effect of Dietary Glycemic Index on Beta-cell Function". The study will determine if increasing the highs and lows of blood glucose levels (glycemic variability) impairs insulin secretion in people with impaired glucose tolerance and/or impaired fasting glucose who are at risk for developing type 2 diabetes. Furthermore, the study will determine whether c...
What is the current status of trial NCT01386645?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2011-07. Estimated completion is 2019-08-01.
What conditions does trial NCT01386645 study?
This clinical trial studies the following conditions: PreDiabetes, Oxidative Stress, Impaired Glucose Tolerance, Impaired Fasting Glucose.
What interventions are being tested in trial NCT01386645?
The interventions under investigation include: low glycemic index (LGI) diet (OTHER), high glycemic index (HGI) diet plus placebo (PLAC) (OTHER), high glycemic index diet plus N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT01386645?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01386645 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
-
Cleaner Air for Lower Cardiometabolic Risk
RECRUITING · NA
-
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.